Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2007-07-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
NCT03619213
A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants
NCT03494907
A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
NCT01803399
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697
A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study
NCT00675701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
20 mg single dose of dapagliflozin
20 mg dapagliflozin
Dapagliflozin
3 x 50 mg tablets, single oral dose
Dapagliflozin
2 x 10 mg capsules, single oral dose
Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
150 mg single dose of dapagliflozin2
150 mg dapagliflozin
Dapagliflozin
3 x 50 mg tablets, single oral dose
Dapagliflozin
2 x 10 mg capsules, single oral dose
Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
400 mg single dose of moxifloxacin
Moxifloxacin
Dapagliflozin
3 x 50 mg tablets, single oral dose
Dapagliflozin
2 x 10 mg capsules, single oral dose
Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
Placebo
Placebo
Dapagliflozin
3 x 50 mg tablets, single oral dose
Dapagliflozin
2 x 10 mg capsules, single oral dose
Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin
3 x 50 mg tablets, single oral dose
Dapagliflozin
2 x 10 mg capsules, single oral dose
Moxifloxacin
Overencapsulated 400 mg capsule, single oral dose
Placebo to match moxifloxacin and dapagliflozin
Overencapsulated 400 mg capsule, single oral dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal screening results including a physical examination, laboratory tests, heart rate, blood pressure, and ECG (electronic measure of the heart)
Exclusion Criteria
* No use of over the counter medications within 7 days of the study
* No use of prescription medicaiton within 1 month of the study
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenn Carlson, MD
Role: STUDY_DIRECTOR
AstraZeneca
Ronald Goldwater, MD
Role: PRINCIPAL_INVESTIGATOR
Parexel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1690C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.